NF1 gene. Therefore, relatively few mutations have been characterized. 5 Sporadic C AE T germline mutations have been described in the literature, one at the nucleotide-1087 of the exon 4 (nucleotide numbering based on that in Estivill et al.) 6 those at 5242 and 5260 of exon 29, 7 and those at 5839 5 and 5842 7 of exon 31. Two cases of point mutations involved the first nucleotide of the codon for Lys-1423, which is the mutational hot spot in NF1. They were AAG AE GAG (Lys AE Glu) in colon cancer and AE CAG (AE Gln) in anaplastic astrocytoma. 8 A formal genetic study of 26 Japanese patients and 74 members of 18 kindreds revealed that 50% of the mutation was novel; with the mutation rate assumed to be 7.3-10.5 ϫ 10
Ϫ5
. 9 Another study on NF1 mutations in Japanese reported single base pair (A-T) insertional mutations at nucleotides-5843, -5844, -5845, and -5846 of exon 31 in one patient and a single A AE G transitional mutation 4 bp upstream from the 3Ј end of intron 31 in two unrelated patients. 10 In 1972, one article from Japan 11 and one from the United States 12 reviewed von Recklinghausen disease and mentioned rare incidences of lung cancers associated with the disease, but gave no details. Since then, three sources have published reports on five cases of lung cancers associated with NF1. [13] [14] [15] In the present study, we screened 37 cases of lung cancer in an attempt to detect possible mutations within the functional GTPase-activating protein-related domain (GRD) of the NF1 exon 24, being the so-called FLR exon. We identified three mutations in three cases of small cell carcinoma, two of which involved amino acid substitution (Glu AE Gly). The remaining mutation was silent.
Materials and Methods

Patients
The 37 patients with primary lung cancers were made up of 17 with adenocarcinoma, 9 with squamous cell
Introduction
The neurofibromatosis type 1 (NF1) gene is a 350 kb gene, encoding mRNA molecular species diversified by alternative splicing at multiple splice sites. [1] [2] [3] [4] The NF1 gene has a very high mutation rate. About 50% of patients are said to have a de novo mutation, but the search for mutations is hampered by the large size of the carcinoma, 9 with small cell carcinoma, and 2 with large cell carcinoma. The nine patients (Table 1) with small cell carcinoma consisted of three women and six men aged from 57 to 75 years.
DNA Samples
DNA was extracted from formalin-fixed, paraffinembedded tissue specimens according to the method described by Impraim et al. 16 The original specimens had been obtained from 37 patients during surgical resection, and paraffin blocks were prepared by routine histopathological procedures. DNA was extracted from both normal tissue and tumor tissue from each patient.
PCR Amplification
DNA samples were amplified by DNA polymerase chain reaction (PCR) and subjected to single-strand conformation polymorphism (SSCP) analysis. Briefly, exon 1 of c-Ki-ras gene was amplified with the following primer pair designed by Cawthon et al. 17 They were (5Ј-
The program of the PCR was 5 min at 95°C once, followed by 30 s at 95°C, 30 s at 52°C, 30 s at 73°C for 35 cycles; then 2 min at 73°C.
The exon 24 of the NF1 gene was amplified with the following primer pair. They were 5Ј-CAAACCTTA TACTCAATTCTCAACTC-3Ј) [forward primer]/(3Ј-TTGGGGTTAAATTCTATCGATCTAATAG-5Ј) [reverse primer]. 18 The program of the PCR was 5 min at 95°C once, followed by 30 s at 95°C, 30 s at 56°C, and 30 s at 73°C for 35 cycles, then 2 min at 73°C. The reaction mixture was made up of 100 ng genomic DNA, 15 pM each primer, 200 µm each deoxyribonucleotide triphosphate, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl 2 , 50 mM KC1, 10% (w/v) glycerol, and 2 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA), to a total volume of 100 µl.
SSCP Analysis
We used the modified method of Cawthon et al. 19 Briefly, PCR products were phenol/chloroformextracted and purified by a Micro-spin Column S-400 HR (Pharmacia P-L Biochemicals, Milwaukee, WI, USA). Appropriate amounts of purified PCR products were mixed with equal volumes of dye solution (95% formamide, 20 mM ethylenediaminetetraacetic acid (EDTA), 0.05% bromophenol blue, and xylene cyanol). After denaturation at 90°C for 5 min, 10-µl samples were immediately cooled on ice and loaded on neutral polyacrylamide gradient gels (10%-20%). Two systems were run for each set of reactions; one was 25 mM Tris, 192 mM glycine, 1 mM EDTA gel at 4°C, and the other was 25 mM Tris, 192 mM glycine, 1 mM EDTA, 5% glycerol gel at 17°C. Electrophoresis was carried out in commercially available apparatus (138 ϫ 130 ϫ 0.75 mm, ATO, Tokyo, Japan). Electrophoresis was carried out at 60 W constant power in the 0.6ϫ TGE buffer. Electrophoresis was run for about 8 h. After electrophoresis, the gels were stained with Silver Staining Kit DNA (Pharmacia Biotech, Piscataway, NS, USA) and the DNA fragments were transferred by exposing the gel to Electrophoresis Duplicating Film (Kodak, Rochester, NY, USA).
Sequencing of SSCP Conformers
Individual SSCP bands were cut out directly from the dried gel and were incubated with 100 µl of the elution buffer (500 mM ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA (pH 8.0), and 0.1% SDS) at 37°C while being shaken overnight, then centrifuged briefly to pellet debris by a modified crush and soak method. 16 A 10-µl aliquot of the supernatant was used directly in a 100-µl PCR reaction mixture. DNA fragments were amplified through the asymmetric PCR in a 100-µl reaction mixture under the same conditions as those for SSCP-PCR analysis, except that the ratio for forward/ reverse primers was 1 : 100. The single-strand PCR products resulting from this amplification were purified by four washes with Ultra Free C-3 (Millipore, Tokyo, Japan). They were sequenced by the dideoxynucleotides chain-termination reaction with [ 35 S]-dCTP using Sequenase, version 2.0 (United States Biochemical, Cleveland, OH, USA). The primer used for this sequencing was (5Ј-ATGTTCCTCAGATTTATCAA TCC-3Ј).
Cloning of PCR Products
Portions of the SSCP-PCR products were cloned into pCRTM II Vector by TA Cloning Kit (Invitrogen, San Diego, CA, USA), then sequenced with Sequencing High and Imaging High (Toyobo, Osaka, Japan). 
Results
The highly conserved FLR exon of NF1 was screened for mutations using SSCP, as described in Materials and Methods. The 37 lung cancers were screened for abnormal bands. None of the normal tissues had any abnormal bands (Fig. 1) . Three of the tumor tissues were positive, all of which had one paired normal band in common. Cases 1 and 7 had one paired normal band and one thick abnormal band at identical positions, as shown in Fig. 1 (lanes 1 and 7) . In case 6, two abnormal bands were seen. All the patients with abnormal bands had been diagnosed with small cell carcinoma and showed typical histology of the disease. After SSCP, all the abnormal bands and corresponding normal bands were cut out, and DNA was extracted and analyzed by direct sequencing as described in Materials and Methods. DNA sequencing showed that abnormal bands from cases 1 and 7 had the same single base replacement, GAA AE GGA, resulting in the amino acid substitution, Glu-1415 AE Gly (Fig. 2B-1 , B-2). This is a novel mutation in accordance with the current knowledge that about 50% of patients have a de novo mutation. On the other hand, in case 6, each abnormal band showed a single base change (A AE G) at the third nucleotide in the codon CCA (Pro-1411) without amino acid substitution (Fig. 2C) reflecting frequent degeneracy at the third nucleotide. These mutations were further confirmed by the subcloning method as described in Materials and Methods (Fig. 3B,C) . The cKi-ras mutation was not found in any of these cases (data not presented).
The four patients with small cell carcinoma ( Table 2 , cases 1, 2, 6, 7) had lymph node metastasis, three of whom (cases 1, 6, 7) with NF1 mutation, had both hilar and mediastinal lymph node metastases. On the other hand, case 2, with no mutation in NF1, had only hilar lymph node metastasis, but no mediastinal lymph node metastasis. The other five patients with small cell carcinoma, who were free of metastasis, showed no mutation in NF1.
Discussion
Among the 37 cases of lung cancer studied, we identified 3 with NF1 mutation. Although the lung cancers included squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma, the NF1 mutants were detected only in the nine cases of small cell carcinoma ( Table 1) . The NF1 mutations identified in this study included two incidences of the same single amino acid substitution, Glu-1415 AE Gly, and one incidence of a silent substitution at Pro-1411 (Table 3) .
According to our SSCP analysis, cases 1 and 7 had only one abnormal band without the paired band. These bands had the same point mutation at the FLR exon. Thus, we concluded that loss of heterozygosity occurred in these cases. On the other hand, two abnormal bands were found in case 6. Because each band showed the same polymorphism, we concluded that they were paired. Several cases of lung cancer in patients with NF1 have been reported in Japan and other countries (see above). As quoted below in more detail, Shimizu et al. 15 failed to detect a deletion in the NF1 gene in a rare case of small cell lung carcinoma occurring in an NF1 Fig. 1 . Single-strand conformation polymorphism analysis of the polymerase chain reaction products. Numbers of the lanes correspond to the case number of each patient with small cell lung carcinoma (Table 2) . Cases 1, 6, and 7 had abnormal bands (see Results for more details) A B-1 B-2 C Fig. 2 . Sequencing of DNA from the single-strand conformation polymorphism-polymerase chain reaction products for the FLR (PhenylalanineLeucine-Arginine) exon of the neurofibromatosis type 1 gene from the three small cell lung carcinomas. A, normal lung tissue; B-1, case 1; B-2, case 7; C, case 6. GAA AE GGA at codon 1415 was indicated for B-1 and B-2, and CCA AE CCG at condon 1411 was indicated for C (see Results for more details) patient, but the possibility remained that there was a point mutation in the conserved region of the gene.
The so-called FLR exon, which is in fact exon 24 of the NF1 gene, extends from Val-1371 to Lys-1423. The Lys-1423 is a potential mutational hot spot identified in several types of tumors, which is known to play a crucial role in the function of NF1. It is located in the GTPaseactivating protein-related domain (GRD) 19, 20 extending from Thr-1175 in exon 21 to Ala-1534 in exon 27a. 21, 22 The NF1 gene product, neurofibromin, contains a GTPase-actavatin protein (GAP)-related domain, or NF1 GRD, which is able to downregulate p21ras by stimulating its intrinsic GTPase.
Li et al. 8 described an amino acid substitution in the NF1 GRD, altering Lys-1423, which occurred in three tumor types, namely, colon adenocarcinoma, myelo- 
dysplastic syndrome, and anaplastic astrocytoma. The GAP activity of the mutant NF1 GRD is 200-to 400-fold lower than that of wild type, but its binding affinity is unaffected. 8 All of the three mutations identified in our study were located in the GAP-related domain close to the mutational hot spot within exon 24.
NF1 mutations increase a patient's susceptibility to various kinds of malignancies. Not only neural crestderived tissues, but other tissue such as myeloid tissue, are known to be susceptible to malignant transformation. In fact, a number of malignant myeloid disorders have been reported; 19, 23, 24 however, several attempts have failed to detect mutations in the GRD of NF1 gene in myeloid malignancies without NF1 phenotypes. 22, 25 Shimizu et al. 15 reported a rare case of small cell lung carcinoma developing in a subject with NF1. Using several chromosome 17-specific polymorphic DNA markers, they looked for NF1 deletions in both primary tumor and metastatic tumors, without success. They did find loss of heterozygosity on chromosome arm 17 p, but not on 17 q (which harbors the NF1 locus); however, since they did not take measures to detect point mutations in NF1, the possibility was not excluded that there was a mutation(s). Fig. 2 by subcloning. A, normal tissue ; B, case 1; C, case 6 (see Fig. 2 and Results for more details)
A C B
In conclusion, to the best of our knowledge ours is the first report on the presence of point mutations resulting in amino acid substitutions in the functional domain of the NF1 gene in small cell lung carcinomas. The mutation alters a Glu residue at codon 1415 in the catalytic domain of neurofibromin, which is invariant among GAP-related proteins, and is therefore likely to be crucial for normal function. Since p21ras GTP is a major regulator of growth and differentiation, mutant nerofibromins resulting from somatic mutations in the NF1 gene might interfere with ras signaling pathways and contribute to the development of tumors. Therefore, a mutation in this region would indicate a poor prognosis.
